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vABSTRACT
Background: Lower back pain is one of the most common health-related complaints in
the adult population. Thirty percent of Americans 65 years and older reported symptoms
of lower back pain in 2004 1. With an aging population, the proportion of people over the
age of 65 is expected to reach 20% by the year 2030. Because of this increase in older
adults, lumbar spinal stenosis (LSS) associated with arthritic changes will also likely
increase. In older adults, lower back pain is most often caused by degenerative lumbar
spinal stenosis. Stenosis is the narrowing ofthe spinal canal, causing pressure on the
nerve roots and is frequently treated surgically. Lumbar spinal stenosis is one of the most
common reasons for back surgery in patients 65 years and older 2. However, risks
associated with surgery increase with age 3-5 and older patients may choose non-surgical
treatment for their lower back pain, including injection treatment.
Injection treatment, usually consisting of anti-inflammatory medications and
analgesics, has improved since the mid-1990's when fluoroscopic guidance was
developed 6. Information about injection treatment for lower back pain is limited,
especially in the older population. An extensive review of published literature regarding
injection treatment revealed a paucity of information about older adults diagnosed with
lumbar spinal stenosis 6-13. In this study, three aims were designed to gain more
information about the effectiveness of injection treatment in older patients with lumbar
spinal stenosis. In the first (retrospective) study, information about receipt of second
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injections and time between injections was collected to examine injection usage. In the
second and third (prospective) studies, information about pain relief and functional return
following injection treatment was collected to examine the effectiveness of injection
treatment in patients age 60 and older diagnosed with lumbar spinal stenosis. To our
knowledge, such results have not been repolted for this population in the literature.
Objective: Injection treatment is a commonly used non-surgical procedure to alleviate
lower back pain in older adults. However, older patients do not have enough information
about how long pain relief will last after treatment or the amount of pain relief and
functional return they will experience. These studies focused on three topics: 1) usage of
injection treatment; 2) effectiveness of injection treatment on pain relief; 3) effectiveness
of injection treatment on functional return. In addition, the variations ofthe effectiveness
were examined by selected patient attributes.
Methods: In a retrospective study, medical records of patients aged 60 years or older
from a high volume dedicated spine center at the University of Massachusetts Memorial
Hospital were retrospectively reviewed. This study included those diagnosed with
degenerative LSS, who had not received an injection for lower back pain within six
months, and whom were treated between June I, 2006 and May 31, 2007.
In two prospective studies, patients scheduled for lumbar injection treatment
between January 1 and June 30, 2008 were selected from the University of Massachusetts
Memorial Hospital Spine Center. Selection criteria included patients age 60 and over,
diagnosed with degenerative lumbar spinal stenosis and no previous lumbar injection
within 6 months or lumbar surgery within 2 years. The Pain sub-score ofthe SF-36
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questionnaire was used to measure pain at baseline and at one and three months post
injection. The Physical Component Score (PCS) of the SF-36 questionnaire and the
Oswestry Disability Index (ODI) were used to measure function at baseline and at one
and three months post injection. Variations in longitudinal changes in scores by patient
characteristics were analyzed in both unadjusted (univariate) analyses using one-way
analysis of variance (ANOVA), and adjusted (multiple regression) analyses using linear
mixed effects models.
Results: In the retrospective cohort, the mean age ofthe cohort was 68, 64% were
female, 59% were married, with a mean Body Mass index of 32 kg/m2. Of 92 eligible
patients, 57% returned for a second injection within six months ofthe first. The mean
number of months between injections was 4.8 for all patients, ranging from 1 to 22
months. When patient characteristics were examined, the only variable that showed a
statistically significant difference was age. Patients aged 70 years and older were found
to be 67% less likely to return for a second injection when compared to patients age 60-
69 (OR=0.33 (0.12 - 0.94)p<.05». When age was examined as a continuous variable,
the odds of having a second injection decreased by 10% for every year aged after age 60
(OR=0.90 (0.83 - 0.99);p<.05».
In the prospective cohort, information was collected on 62 patients. Mean Pain
scores improved significantly from baseline to one month (14.1 points), and from
baseline to three months (8.3 points). Post injection changes in Pain scores varied by
Body Mass Index (BMI) and baseline emotional health. Based on a linear mixed effects
model analysis, higher baseline emotional health, as measured by the SF-36 Mental
viii
_______-'C."o"'mgponent Score (MCS>50), was associated with greater reduction in pain over three
months when compared to lower emotional health (MCS<50). In patients with higher
emotional health, Pain scores improved by 14.1 (p<.05: 95%CI 6.9, 21.3). Mean
function scores for both the PCS and om also improved significantly from baseline to
one month (2: 3 points), but not at three months. Post injection changes in PCS and om
varied by age, Body Mass Index (BMI), co-morbidities and emotional status. Based on a
linear mixed effects model analysis, higher baseline emotional health, as measured by the
SF-36 Mental Component Score (MCS2:50), was associated with greater improvement of
function at one and three months when compared to lower emotional health (MCS<50).
In patients with higher emotional health, om improved by 17.8 points (p<.0001) over
three months, and PCS improved by 6.1 points at one month and 4.6 points at three
months.
Conclusion: Patients over age 70 do not return for repeat injection as frequently as
patients age 60-69. In addition, each year a patient ages over age 60, they are 10% less
likely to return for a repeat injection. Lower back pain in older adults with LSS is
clinically significantly alleviated after injection treatment. In addition, injection
treatment for LSS is associated with return of lost function needed for daily living
activities in older adults. Pain relief and functional return varies by patient personal and
clinical characteristics. Higher emotional health was associated with more pain relief and
more functional return experienced over three months following injection treatment.
Additional information is needed about why older patients do not return for second
ix
injections at the same rate as younger patients and how emotional health affects response
to injection treatment in older adults.
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ICHAPTERl
Outcomes of injection therapy treatment on lumbar spinal stenosis
in older adults: A systematic review of the literature
INTRODUCTION
Lumbar stenosis is a condition that causes pain of the lower extremities and/or
back when nerve roots are compressed by narrowing ofthe lumbar spinal canal. Lumbar
stenosis occurs more frequently in aging adults 14and affects five of every 1,000
Americans over age 50 15. Historically, laminectomy has been the surgical treatment of
choice for lumbar stenosis in adults 16. Laminectomy decompresses nerves near the
spinal column thus alleviating pain and may return some lost functions. However,
laminectomy procedures have been shown to have up to a 64% failure rate, defined as
local tissue trauma and postoperative spinal instability 16. Older adults have a greater risk
of complications following surgery than younger patients including dementia 3, infection
4 and respiratory, cardiac and urinary tract complications 5. Due to the high failure rate of
this procedure, many physicians and patients choose non-surgical methods for treatment
17. An emerging treatment to alleviate symptoms for lumbar stenosis is to inject steroids
and analgesics. Although this procedure initially had many complications including
spinal cord injury, myelopathy and spinal hematoma, procedure techniques have
improved and many patients have experienced satisfying and long-lasting relieffrom
lower back pain 6. In addition, the development of fluoroscopic guidance has enabled
physicians to deliver injected medications more accurately, causing fewer complications
26. However, there is little evidence available to predict outcomes from the procedure
within older adults age 65 and older.
The purpose of this systematic review is to summarize the major findings in the
current literature about pain, function, co-morbidities and complications following
injection therapy used to treat lumbar stenosis in adults with a focus on older patients.
This systematic review will summarize outcomes for people diagnosed with lumbar
stenosis and receiving injection therapy. With the information presented in this review,
primary care physicians may be able to provide more effective treatment and referrals for
their older patients.
METHODS
SEARCH STRATEGY:
Literature search
Current literature published on this topic, were queried in MEDLINE and The
Cochrane Review. The search terms "injection lumbar stenosis", "nonsurgical lumbar
stenosis" and "conservative lumbar stenosis" were used to identify peer-reviewed articles
published between 1996 (when fluoroscopic was developed and used in clinical practice)
and 2006. Additional studies were identified using references from these studies.
Validity Assessment
All studies identified in the search were reviewed to determine if they met
inclusion criteria and described below. Final assessment was made for both inclusion and
exclusion criteria upon review of data available in each study. References were also
3reviewed for potential studies addressing the research question. After review of all the
included studies, data were abstracted and entered in a table.
Inclusion criteria:
To be reviewed, studies had to meet these criteria: 1) be in English, 2) published
between October 1, 1996 and October 1, 2006, 3) subjects were adults diagnosed with
lumbar stenosis and treated with injection therapy, and 4) outcomes measured were pain,
function, comorbidities and perioperative complications. Since fluoroscopic guidance
was used to more accurately deliver spinal injections in the mid-1990's, study inclusion
was limited to studies published after 1995.
Exclusion criteria: Studies were excluded from the review if they I) were case studies,
2) included subjects that had previous back surgery, 3) included subjects that had disc
conditions, or 4) included subjects that were receiving other therapy (physical therapy,
medications) combined with injection therapy. Studies evaluating multiple treatments
would not allow attribution of outcomes to injections.
Analysis
Data extracted from the included studies were entered in a table that included
author, year of publication, number of participants, mean age, effect/results, and whether
or not information was collected on pain, function and complications for both people over
and under age 65. Following identification of these studies, information was extracted on
study design, sample size and age of participants. The key information extracted from
the studies included outcome data from injection treatment, especially in patients over
age 65.
4RESULTS
The initial search identified 35 articles (Figure I). Twenty-three study abstracts
were excluded for the following reasons: six included patients with disc conditions, five
were reviews, four were letters to the editor, three evaluated non-surgical treatment only
(but not specifically injections), two combined injections with other treatments, two were
published in a foreign language and one was a case study.
Twelve studies were then reviewed and five were excluded based on the
following criteria: two included patients with disc conditions, two did not specify lumbar
stenosis and one combined injections with other treatments. Seven studies were
identified as meeting selection criteria and are listed in Table I. Results extracted from
each study are included in Table 2.
Diagnosis of Lumbar Stenosis
In the reviewed studies, lumbar stenosis was defined using a variety of criteria
including: history of any leg and lower back pain, failed conservative management of
pain symptoms and radiographic evidence showing narrowing of the spinal canal. Ofthe
seven studies included, four specified confirmation of lumbar stenosis by magnetic
resonance imaging and one required "radiographic evidence" oflumbar stenosis.
Conditions identified as being associated with lumbar stenosis ranged from
spondylolisthesis to spinal canal narrowing to nerve root compression. In addition, no
patients had known lumbar disc disease. In four of the seven studies, pain was specified
as one of the most useful diagnostic factors for lumbar stenosis. This ranged from lower
back pain to radicular pain. In three of these four studies, patients' symptoms could not
5________hle.J:es.oly..ed.hy-c~ons.ervatiyetreatment in order to be included in the study samp-'-'le"-.-'I""ncct""w"'o'-- _
ofthe four studies, pain relief from spinal flexion was also used as inclusion criteria.
Age
Information on the ages of patients was not consistently reported in the seven
reviewed studies. In five ofthe seven studies, age ranges were reported and included
patients ranging from age 17 to 92. Age means ranged between 54 and 77 years. None
of the seven studies included information specifically on patients over age 65.
Follow-up
Follow-up periods varied greatly in the seven studies included in this review.
Following baseline assessment and injection treatment for lumbar stenosis, the follow-up
periods ranged from one week to 24 months. In three of the seven studies, only one
follow-up period was used. In one of the studies, two follow-up periods were used and in
three of the studies, three or more follow-up periods were used. In two of the seven
studies, follow-up assessment did not begin until at least one month after the injection
was given.
Measures:
A wide variety of instruments were used to assess pain and function in all seven
studies. The list of pain instruments included: Visual Analog Scale 6,9.11, Verbal
Numeric Pain Scale 7 and the Stucki Questionnaire 8. The list offunction measures
includes the Roland-Morris Disability Questionnaire 7, the Stucki Questionnaire 8, the
Oswestry Disability Index 10 and walking or standing tolerance tests 6.12. Neither pain
6nor function measures were consistent throughout the included study designs. Function
measurements were particularly varied.
Pain
Pain relief was quantified in six of the seven studies and all reported relief
following treatment by injection. No studies reported information specific to patients
over age 65. Six studies identified examined the results of epidural steroid injection on
pain, and all studies showed an improvement following treatment in people of all ages.
Pain measures varied across studies and the pain scale most often used was the Visual
Analog Scale, reported in four studies 6.9-11. These studies reported a reduction in pain,
with the most notable result reported in Botwin's study showing at least a 50% reduction
in pain in 75% of patients. A similar result was found in Barre's study, which showed at
least a 50% reduction in pain, but only in 35% of patients. Two of the studies focused
their reports of pain relief at several follow-up periods. The first study reported
"continuous improvement" at one, two, three, six and twelve months 9. The second study
was the most difficult to interpret, assessing pain using a combination of scales for pain,
function and satisfaction 8. The criteria for improvement in this study included at least a
two-point increase on each ofthe three scales. It was not possible to assess pain relief
separately from these other, more global issues.
Function
Five of the seven studies included in this review assessed function. However,
function was assessed differently in every study and used a wide variety of instruments.
7While some studies used standardized instruments, others used individualized
measurements of function such as walking distance tests.
In four of the five studies, improvement in function was reported following
epidural steroid injection, but to varying degrees 6-8. 10. Of the five studies, four assessed
function using standardized instruments, such as the Oswestry Disability Index and the
Roland Morris Questionnaire, and all reported improvement in function in at least one-
third of the patients. All four studies reported an improvement in function in at least one-
third of the patients. The fifth study also reported improvement in function, but did not
specify the degree of improvement 12. This was primarily due to the design of the study,
which compared three groups of patients classified by their functional abilities at baseline
(dysfunctional, emotional adaptors and highly functional). All three groups were
reported as showing improvement at l2-month follow-up.
Two of the five studies assessed function by evaluating and/or measuring walking
distances 6.12. The first study found a significant improvement in 64% of the patients 6
and the second study found a significant increase in walking distance at one-week follow-
up, but not at one-month or three-month follow-up 12.
The study most difficult to interpret (Cooper, 2004) did not assess function alone,
but as a contributor of an overall "improvement" score 8. Measures for pain, function and
satisfaction were combined. However, an overall improvement was seen in 55.8% of
patients when combining the three scales.
8Complications and Comorbidities
Complications and co-morbidities were rarely discussed in detail in any ofthe
studies. For example, Barre, et al. reported no major complications in the study group
following epidural steroid injection, such as infection, dural tear, or nerve root injury. It
was also reported that patients with spondylolisthesis were more likely to have successful
outcomes than people without spondylolisthesis. Another example of a lack of
information concerning complications, was in Igarashi's prospective cohort, where it was
reported that one patient experienced dural puncture and was excluded from the analysis
9. Co-morbidities were not discussed in any of the studies.
DISCUSSION
This systematic review revealed a lack of research about clinical care for lower
back pain in older adults. Deficiencies in this area of research include: I) a small number
of studies; 2) generally small sample sizes; 3) inconsistent or non-standardized
instruments for measuring pain relief and function return, 4) general lack of longitudinal
long-term follow-ups, 5) lack of focus on the older populations, and 6) lack of focus on
lumbar spinal stenosis caused by degenerative changes. These deficiencies advocate for
more studies focused on older populations. To provide evidence-based recommendations,
additional studies are needed.
In current literature, specific information is lacking about pain relief and function
after injection treatment in older adults. Although all the studies reviewed included
patients over age 65, no results specific to elder patients were reported, which limits the
ability to make conclusions or recommendations for this age group. Older adults are
9often poor surgical candidates, are frequently prescribed multiple medications for other
chronic diseases and are at risk of drug interactions or adverse reactions 18. Thus, the
need for better data about injection effectiveness in this important patient group is urgent.
As each study reviewed included people in this age range, it would be beneficial to
extract information regarding treatment for low back pain specifically in older adults,
especially since lumbar stenosis is a common diagnosis among aging adults. For
example, six ofthe seven studies reported improvement following treatment 6.11 , but did
not stratify the results by age group. If older patients responded differently to treatment
compared to younger patients, it was not possible to make this distinction in this literature
review.
The effectiveness of injection treatment for lumbar stenosis was measured using a
variety of instruments designed to assess pain and function in this review. Also, the
studies identified used a variety of study designs, inclusion criteria and follow-up periods.
Inconsistencies in the assessment of injection treatment make it difficult to provide
recommendations to primary care providers, patticularly for optimal care of older adults.
Several inconsistencies were found concerning study design. The first problem
with these studies was the clinical definition of lumbar stenosis, i.e., a narrowing of the
spinal cord. The studies in this review identified several conditions as the cause of
lumbar stenosis. For exmnple, arthritic changes and displaced disks are both causes of
lumbar spinal stenosis, but were combined in the studies. Importantly, magnetic
resonance imaging was used as confirmation of the diagnosis in the majority of the
studies before injection was used. The presence of pain associated with lumbar stenosis
10
was also commonly used as a criterion for a diagnosis. However, the underlying causes
for the development oflumbar spinal stenosis were not stratified in the analyses. Future
research may better assess the effectiveness of injection treatment by focusing on more
specific diagnoses.
The second problem in the assessment ofthe degree of pain relief and functional
improvement in the reviewed studies was a difference inthe length of follow-up periods.
Improvements were seen in all the follow-up periods, but the studies ranged from one
week to one year. For the primary care provider, the recommendation of injection
treatment may rely on patient preferences for either long or short term relief. For
example, an inactive older adult's preferences may differ from those of a younger, more
active patient. While an older patient may be focused on the next three months, a
younger patient may prefer to receive treatment that will provide relief for the next five
years. These differences in outlook should affect what type of treatment is
recommended. Based on the findings of the studies included in this review, future
research should include a more consistent range of follow-up periods to more accurately
assess both the long and short term effectiveness of injection treatment.
The third problem was the lack of group-specific information that is useful to
advise elderly patients. Though all the studies in this review included people over age
65, none focused on this group specifically. Since treatment for lower back pain caused
by lumbar spinal stenosis has been increasing over the last fifteen years, especially in
patients over age 60 years 19, more information is needed about this age group. If
primary care practitioners are making decisions about follow-up care for their older
11
________patilmt1UYith lumbar stenosis, it is difficult to make assumQtions about injection treatment
based on the majority of these studies. It is evident from the design ofthese studies that a
more clearly defined focus on older adults is needed for future research.
The fourth problem found in this review concerns the variety of instruments used
to assess both pain and function. Because of this variety, it was not possible to combine
these results to offer an overall quantitative measurement of either pain or function, thus
an evidence-based recommendation cannot be formulated. However, a general
improvement in function and decrease in pain was seen in all the studies reviewed. This
information could be useful to the primary care provider when deciding whether injection
treatment is appropriate. Although a general improvement was seen throughout the seven
studies, it should be noted that the degree of improvements varied among studies. The
variability was primarily due to the complexity of measuring an improvement that is self
reported, such as pain and function. According to factors such as age, lifestyle, mental
health and comorbidities, every patient's perception of pain and function is unique, and
responses will vary. The differences in what patients consider acceptable should be
considered when making decisions about follow-up care for lumbar stenosis.
While injection therapy for lumbar stenosis is a common decision in the
management of lower back pain, limited data are available to date concerning treatment
of lumbar stenosis by injection therapy, especially in older adults. The number of studies
included in this review, though limited in number, generally do show an improvement in
pain and function. However, more research into this promising procedure is necessary.
Several important issues should be considered in future research. First, studies are
12
needed focusing on people over age 65. Since arthritis increases with age, and lower
back pain is one of the most common complaints reported by older patients, more
research should focus on lumbar spinal stenosis caused by arthritic changes. Of primary
interest should be relieffrom pain, functional return, comorbidities and post-injection
complications. The second issue may be on differentiating between the effects of steroid
versus anesthetic injections in the diagnosis and treatment of lumbar stenosis. It may be
beneficial to the patient iffuture injections can be specific to the diagnosis. This would
be particularly beneficial to people classified as older adults, who are considered a more
vulnerable population and thus more prone to complications especially from multiple
medications. As only one of the included studies included a randomized control trial 12,
this method may be a particularly useful approach to determining the effectiveness of
specific treatment regimens. The third issue is to more clearly define assessment of
functional return following treatment by injection. For the older population, this may
involve an evaluation of function in terms of a less mobile and less active group. The
level of function achieved following treatment should be compared to both previous
function and satisfaction with function. While functional return is generally a secondary
consideration to pain relief, it is an important aspect of patient satisfaction and emotional
health.
No studies have specifically documented the effects of injection therapy for
lumbar stenosis in older adults, over age 65. With a growing number of people in this
age group, it would be beneficial to older adults if the effects of injection treatment were
better understood for their age group. Although more studies have been published
13
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compared to the last ten years), specific information about older adults is not available to
date. If future research provides information on older adults, practitioners treating people
in this age group could make more informed decisions regarding optimal treatment. Older
patients may experience fewer procedures and more effective pain relief for low back
pain caused by lumbar stenosis. An important result would be that general practitioners
treating older adults would be equipped to make more informed healthcare decisions for
the treatment of lower back pain.
The problems identified about injection treatment in older patients in this review
have served as an outline for the research studies conducted and described in this
dissertation. There were several issues found to be problematic in past literature. These
problems included small sample sizes, non-standardized instruments for measuring pain
relief and functional return, inconsistent follow-up periods, lack of focus on specific
diagnoses and lack of focus on older populations. These deficiencies were considered in
the design of three studies. All three studies focused on patients aged 60 and over, with a
specific diagnosis of lumbar spinal stenosis caused by arthritic changes. Two prospective
studies used standardized instruments for the measurement of pain and function as well
as consistent follow-up periods. Sufficient sample sizes for these studies, as well as one
retrospective study, were computed using power analyses to ensure the detection of
meaningful changes in pain and function scores following treatment. These issues were
considered in the design ofthe studies described in Chapters 2, 3 and 4.
14
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I Abstracts (35) I
Excluded:
6 included disc problems
5 reviews
4 letters
3 injections not evaluated
2 included other treatments
2 not in English
1 case study
Studies (12) I
Excluded:
2 included disc problems
2 did not specify stenosis
1 included other treatments
I Included (7) I
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Table 1.1: Studv characteristi
--
Overall
Author (year) N Mean Study Design Pain Complications Function
Age Comorbidities
Barre (2004) 95 69 Retrospective -V -V -V
Cohort
Cooper (2004) 52 69 Retrospective -V * -V
Cohort
Ie:arashi (2004) 58 71 Prospective cohort "\j * *
Ng(2004) 62 62 Prospective cohort "\j * "\j
55 40
Botwin (2002) 34 77 Prospective cohort -V * -V
(range
62-87)
Rivest (1998) 21 54 Prospective cohort -V * "\j
2
Fukusaki (1998) 53 70 (A) ReT * * -V
69 (B)
72(C)
* Not included in study
16
Table 1.2: Outcome followinl!: treatment bv iniection.
Lumbar Stenosis Age Follow- Pain Function Complicatio Outcome
Diagnosis range up Measure Measure nsand
Period(s) Comorbiditi
es
Barre Back or bilateral leg 40 - 91 I) I week Verbal Roland-Monis Improvement in pain J
(2004) pain 2: 3mos. Numeric Pain Disability None reported. Improvement in functio
Scale Questionnaire I
Cooper I) Radiculopathy 50 - 90 I) I week Stucki Stucki Questionnaire 55.8% showed improvejent at I
(2004) 2) Radiographic 2) I month Questionnaire month followup
evidence 3) 3 mos. • 37.2% showed improvement at I year
4) 12 mos. followup I
5) 24 mos.
Igarashi I) Computed 45 -92 I) I week Visual Accidental dural Low back pain relieffor 12 months
(2004) tomography 2) I month Analog Scale puncture
2)MRI 3) 2 mos. reported in one
4) 3 mos. • patient.
5) 6 mos.
6) 12 mos.
Ng I) Unilateral radicular I) 3 mos. Visual I) Oswestry 37% had 2: 10% reduction in
(2004) pain Analog Scale Disability Index Oswestry Disability Indt
2)MRI • 2) Low Back •
Outcome Score
Botwin Lower back and 62 - 87 I) 2 mos. Visual I) Roland 5-point 75% had 2: 50% improvrent in pain
(2002) radicular pain 2) 12 mos. Analog Scale scale 64% i walking2) Wa\king/ • 57% i standing
standina tolerance test
Rivest I) Computed 17 - 86 I) 2 weeks Visual 38% stenosis patients sh0wed
(1998) tomography Analog Scale improvement I
2)MRI • • 61% herniated disc patients showed
3) Electromyography imorovement I
Fukusaki I) Plain X-rays I) I week Walking distance None reported No significant differen1 between the
(1998) 2)MRI 2) I month three groups.
3) Computed • 3) 3 mos. •
tomography
* - Not included in the study. MRI - Magnetic Resonance Imaging
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CHAPTER 2
Return for repeat injections to treat lower back pain in older patients
-----------.w.,.'ith-degeneratlve ImnbarspinaI-stenosis:-A-retrospective-study-----------
INTRODUCTION
Lumbar spinal stenosis (LSS) is a common condition that causes pressure on the spinal
cord and nerve roots, resulting in lower back and leg pain. LSS is commonly caused by
degenerative changes in older adults. Treatments to reduce pain include both surgical
(laminectomy and/or lumbar fusion) and non-surgical (physical therapy, medications, injections)
interventions. Lumbar surgery to treat LSS has been steadily increasing in the U.S. since 1990,
especially in patients age 60 and older 19. However, laminectomy procedures have shown as
much as a 64% failure rate (defined as local tissue trauma and post-operative spinal instability)
16. As a result, many physicians and patients choose non-surgical methods for treatment 17. One
commonly recommended treatment to alleviate symptoms for LSS is injection therapy, with
medications containing steroids and/or analgesics. Since the development of fluoroscopic
guidance in the mid-1990's, injections have been delivered more accurately and many patients
have experienced satisfying pain relief 6. As the proportion of older adults in the general
population grows each year, it is expected that degenerative changes associated with LSS will
increase as well. Older patients may likely continue to seek alternative, less invasive treatments
for their lower back pain. However, much of the research to date has been conducted among
younger patients with LSS 6.14-16.
The goal of this retrospective study ofmedical records, was to quantify the percent ofthe
Qlder adult LSS population (people 2: age 60) in the University of Massachusetts Medical Center
Spine Clinic who required a second injection and to determine the mean time interval between
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first and second injections. In this paper, we report on the outcomes of 100 patients (2:age 60)
diagnosed with LSS, who received steroid and/or analgesic injections. These data are important
when counseling patients who are considering injection therapy. To our knowledge, research on
repeat injections in older adults has not been published to date.
METHODS
Patients
All patients who received a lumbar injection in the UMass Memorial Hospital Spine
Center between June I, 2006 and May 31, 2007 and were age 60 and over were eligible for
review. Exclusion criteria included a diagnosis other than lumbar spinal stenosis (confirmed by
Magnetic Resonance Imaging), a previous lumbar injection received within 6 months or lumbar
surgery within 5 years ofthe baseline injection. Subject selection was accomplished in 2 phases.
I) Using billing records, 117 patients were identified that were age 60 or older, had received an
injection between June I, 2006 and June I, 2007, and had been assigned a diagnosis code of
724.02 (LSS) or 724.2 (lumbago). 2) After medical record review, 17 patients were excluded
for one of the following reasons; a) having received injections in locations other than the lumbar
region ofthe spine, b) having a diagnosis other than LSS, c) having primarily disc related
problems, or d) receiving an injection that was not an epidural. After paper medical record
review, an additional 8 patients were excluded for having received injections in locations other
than the lumbar spine, for having received lumbar surgery within the 5 years prior to their first
injection date or for having a diagnosis of a musculoskeletal disorder that may conflict with
injection effectiveness. The final cohort consisted of 92 patients (Figure I).
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Data Collection
A structured, standardized data collection sheet was designed to include collection of the
following variables: patient name, medical record number, birthdate, gender, height, weight,
race, physiatrist name, marital status, diagnosis code, Magnetic Resonance Imaging (MRI) date
and location, vertabrae involved, physiatrist diagnosis and injection information (dates,
anatomical location, injection type and Visual Analogue Scores). Pain level was measured by
the Visual Analogue Scores (VAS) and was taken at two time points; baseline and one week
following lumbar injection. MRI reports and procedure notes were reviewed for information
regarding diagnosis and injection details. To address LSS severity, a co-investigator (orthopedic
physician) reviewed medical records. Using methods outlined in previous literature 13 severity
scores were assigned after careful review of Magnetic Resonance Images. Five variables were
collected by MRI review; location of stenosis within the lumbar (level and side), number of
moderate to severe levels, severity (mild, moderate or severe) and mid-sagittal diameter.
Information about medical history, smoking and alcohol consumption was deemed to be
inconsistent within medical records. Although these factors are potentially important, they were
not evaluated in this study.
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Fieure 2.1: Flowchart of patient selection.
-----1-----'1-1-7-patients-identified-from-billing-reeords--I---------------------
(Age 60+, received injection, diagnosis code)
17 patients excluded by medical record review
(electronic)
8 patients excluded by medical record review
(paper)
N = 92
Final Cohort
No lumbar injection: 8
No LSS: 5
Primarily disc problems: 3
No epidural: 1
No lumbar injection: 5
Lumbar surgery (in last 5 years): 2
Parkinson's Disease: 1
Collected data were computerized using a Microsoft ACCESS 20 database specifically
designed for this study. Two techniques were used to reduce data entry errors: 1) a data entry
screen using Microsoft ACCESS was designed to look identical to the data collection sheet, and
2) drop-down menus were used wherever possible. All data were entered by a trained research
assistant in the Orthopedics Department, then verified by the first author (verifying every tenth
record).
All variables were examined for distributional characteristics using scatter plots, means,
medians and ranges. Key clinical variables derived from the data include; I) age at first
injection, 2) Body Mass Index (BMI) computed as weight (kg) divided by body height in meters
squared, 3) time between the first injection and second injections (months), and 4) severity of
LSS (mild, moderate, severe).
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Statistical Analysis
Using the statistical software Intercooled STATA 9.0 21 , descriptive statistics including
means, number and percentages of age, gender, marital status, body mass index, visual analog
scores and disease severity were computed. Associations of receiving a second injection within
six months of the baseline injection with gender, age, baseline VAS, BMI, marital status and
LSS severity were examined using logistic regression models. Pilot data indicated second
injections were most often received within six months of the first injection. Logistic regression
models were used to examine this timeframe. Further, Cox Proportional Hazard Regression
models were used to explore the relationship of time from baseline injection to the immediate
next injection for patient characteristics.
RESULTS
The cohort consisted of 92 patients, 64% female and 59% married (Table I). The mean
age was 68 years and the mean Body Mass Index was 32.1 kg/m2. Mean baseline pain score,
measured using the Visual Analogue Score, was 5.5 (SD=2.9). Magnetic Resonance Imaging
(MRI) was only available for 35 patients at baseline, where 80% were classified as having LSS
severity of moderate to severe and 20% were classified as mild.
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Table 2.1: Patient Characteristics.
Variable N % (SD)
Overall 92 100
Age (years)
Mean 68 (5.0)
Gender
Males 33 36
Females 59 64
Marital Status
Not Married 38 41
Married 54 59
BMI (kg/m2)
Mean 32.0 (7.3)
VAS - baseline (1-
10)
Mean 5.5 (2.9)
VAS - I week (1-10)
Mean 3.0 (3.0)
LSS Severity
Mild 7 20
Moderate to Severe 28 80
Mid-sagittal
Diameter
Mean 11.1 (2.7)
Characteristics of patients receiving a second injection versus not receiving a second
injection within six months were reported in Table 2. Ofthe 92 patients, 52 (57%) received a
second injection within 6 months ofthe first, where 52% were male, 65% were between the ages
of 60 and 70 years, and 65% were considered obese to morbidly obese. Chi-square tests were
used to compare differences in the probability ofreturning for second injections between patient
characteristics categories (Table 2). Returning for second injections within six months from
baseline differed significantly (p<.05) between age groups (60-69y versus 70y+).
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Table 2.2: Receipt of second injections within 6 months in lumbar spinal stenosis older
patients by patient characteristics.
Received second Did not receive second
------¥adable----.....Categodesi -'injection_within_6, .inj.edion_withinJi'-- _
months months
n (%) n (%)
52 (57) 40 (43)
17 (52) 16 (48)
35 (59) 24 (41)
41 (65) 22 (35)
11 (38) 18 (62)
20(54) 17(46)
23 (64) 13 (36)
5 (50) 5 (50)
16 (62) 10 (38)
18 (62)
9 (60)
Overall
Gender
Age *
VAS (Baseline)
BMI (kg/m2)
Marital Status
LSS Severity
Male
Female
60-69y
70+y
:'05
>5
~ormal (18.5-24.9)
Overweight (25-
29.9)
Obese (30-34.9)
Morbidly Obese
(>35)
Married 21 (55)
~otMarried 23 (43)
Mild 5 (71)
Moderate/Severe 19 (68)
11 (38)
6 (40)
17 (45)
31 (57)
2 (29)
9 (32)
*P<.05 (based on chi square analysis to compare receipt of second injection between groups)
A statistically significant difference in rate of return for second injection was seen in the
two age groups, 60-69 and 70+ (Table 3). Based on logistic regression modeling, patients age 70
and older were found to be 67% less likely to receive a second injection within 6 months of the
first (OR=O.33: 95%CI; 0.13 - 0.82). When age was included in the model as a continuous
variable, patients were 10% less likely to return for a second injection within 6 months of the
first for every year aged over 60 (OR=0.90 (0.83 - 0.99);p<.05). This relationship was examined
graphically and confirmed. Gender, baseline VAS, BMI, marital status, LSS severity and co-
morbidity scores were not associated with a repeat injection within 6 months of the first
injection.
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Table 2.3: Unadjusted odds ratios (OR) for second injections by patient characteristics
Patient Characteristics "OR (95% CI)
Gender (males vs. females) 0.73 (0031 - 1.71)
----1\.-gF(T"1J'eaY) 0;90-(0;83=0;99)*-------------
Age (70+ vs. 60-69y) 0.33 (0. I3 - 0.82)*
Baseline VAS (>5 vs.>5) 1.50 (0.59 - 3.84)
BMI (Obese vs. non-obese) 1.13 (0.46-2.79)
Marital Status (Married vs. not 1.09 (0.47-2.52)
married)
LSS Severity (mild vs. 0.84 (0.14-5.22)
moderate/severe)
Based on logistic regression; * p-value <.05
In a multiple regression analysis examining the same variables (Table 4), age was again
found to be the only variable significantly associated with receiving a second injection within 6
months of the first. Patients age 70 and older were found to be 67% less likely to receive a
second injection within 6 months of the first (OR=OJ3 (0.12 - 0.94».
Table 2.4: Adjusted odds ratios (OR) for second injections by patient characteristics.
Patient "OR (95% CI)
Characteristics
Age group (70+) 0033 (0.12 - 0.94)*
Sex (males) 0.77 (0.28 - 2.14)
Marital Status 0.83 (0.29 - 2.35)
Baseline VAS 1.42 (0.53 - 3.79)
Based on logistic regression; * p-value <.05; LSS severity was not included in the adjusted model since data was
limited.
Time between baseline and second injection was available for 65 patients and reported
for each patient characteristic in Table 5. The remaining 27 patients did not receive second
injections within the follow-up period, but continued to use the UMass healthcare system.
Patient characteristics are compared between the two groups in Table 6 and were similar.
Among the patients having a second injection, the mean time between injections was 4.8 months.
Wilcoxon rank tests were computed to compare time between injections by patient
characteristics. Because the cohort consisted of a high percentage of those in the morbidly obese
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category, BMI groups were collapsed to morbidly obese vs. not morbidly obese. There were no
significant differences between the patient characteristics categories.
Associations of any repeat injection within 6 months of the first were examined in three
models and are presented in Table 7. Modell included as predictors age, sex, BMI, marital
status and VAS. In this model, age was not a significant variable, but approached statistical
significance (p=0.08). Model 2 included predictors age, sex, marital status, and VAS. Age
effect again approached statistical significance (p=.06). Model 3 included predictors age, sex,
BMI, marital status, VAS and an interaction term between BMI and age. The results indicated
there was no interaction between BMI and age (p=0.17). The relationship between age and
months between injections is shown in Figure 2.
Table 2.5: Months between first and second injections in older patients with
lumbar spinal stenosis by patient characteristics.
Variable (n) Mean (SD) Median (range)
2.4 (.73 - 19.9)
2.0 (.46 - 17.9)
2.5 (.46 - 11.9)
1.9 (.66 -7.9)
2.1(.5-19.9)
1.7 (.46 - 12.6)
2.1 (.5 -12.6)
2.2 (.46 - 19.9)
1.7 (.66 - 5.6)
2.2 (.46 - 17.9)
2.1 (.5 - 6.9)
2.4 (.86 - 19.9)
3.3 (2.9)
2.9 (2.3)
3.4 (3.1)
4.1 (4.9)
4.2 (4.7)
3.5 (3.5)
3.7(4.0)
3.7 (3.6)
2.6 (2.0)
3.8 (4.2)
2.8(2.1)
5.2 (5.6)
Overall (65) 3.7 (3.9) 2.1 (.46 - 19.9)
Gender
Male (21)
Female (44)
Age
60-70 (49)
Over 70 (16)
VAS - Baseline
~ 5 (24)
> 5 (27)
BMI (n)
Normal (5)
Overweight (20)
Obese (21)
Morbidly Obese (13)
Marital Status
Married (39)
Not Married (26)
LSS Severity
Mild (6) 2.0 (2.4) 1.0 (.5 - 6.9)
Moderate/Severe (22) 3.1 (2.3) 2.3 (.46 - 8.7)
Wilcoxon Rank tests were conducted on mean time between injections between categories.
No p-values were < 0.05. (BMI was evaluated as non-obese (normal to overweight) vs.
obese (obese to morbidly obese).
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Table.2.6.:---Cnmparison of censored_and uncensored-patients----------------
Characteristic Uncensored Censored
n=65 n=27
Age (mean (SE»
Female (n ('Yo»
Married (n ('Yo»
67 (.59) 69 (.99)
44 (67) 15 (56)
39 (60) 15 (55)
Table 2.7: Multi-variable adjusted rate ratios (RR) and 95% confidence intervals (CI) of
time between first and second injections using a Cox Proportional Hazard Regression.
Patient Characteristics RR p-value
(95% CI)
0.54(0.28-1.07)
0.70 (0.38-1.29)
0.91 (0.51-1.63)
1.00 (0.54-1.84)
1.35 (0.75-2.45)
0.53 (0.28-1.03)
0.80 (0.44-1.44)
0.92 (0.51-1.68)
1.34(0.75-2.37)
0.52 (0.21-1.31)
0.70 (0.38-1.29)
0.89 (0.45-1.76)
1.00 (0.54-1.89)
Modell
Model 2
Model 3
Age (70+ VS. 60-69)
Sex (Male vs. female)
BMI (Obese vs. not obese)
Marital Status (Married vs.
not)
VAS-Baseline (>5 VS. <5)
Age (70+ VS. 60-69)
Sex (Male) VS. female
Marital Status (Married vs.
not)
VAS-Baseline (>5 vs <5)
Age (70+ VS. 60-69)
Sex (Male VS. female)
BMI (Obese VS. not obese)
Marital Status (Married VS.
not)
VAS-Baseline (>5 VS. <5) 1.36 (0.75-2.48)
Age*BMI interaction 1.1 0 (0.29-4.14)
NS (.08)
NS
NS
NS
NS
NS (.06)
NS
NS
NS
NS (0.17)
NS
NS
NS
NS
NS
Model I: Age, gender, BMI, marital status, VAS. Model 2: Age, gender, marital status, VAS.
Model 3: Age, gender, BMI, marital status, VAS and age'BMI interaction term. NS~Not Significant
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Figure 2.2: Number of months between first and second injection by age
;'i.'j
DISCUSSION
The overall finding of this study provides the orthopedic community with three valuable
pieces of information. I) More than half of all patients over age 60 will probably need a second
injection within 6 months of the first injection, 2) Patients over age 60 will likely feel pain relief
for up to 5 months, and 3) Patient characteristics such as age and BMI may playa part in how
well they respond to treatment. In this cohort, the majority of the patients received a second
injection within six months (57%). However, when stratified by patient characteristics, there
were no significant differences between patient sub-groups except by age. The main finding of
this study was a significant difference in patients by age, where older patients were less likely to
return for a second injection compared to younger patients. In this clinic, patients were
encouraged to make an appointment for another injection if the first injection did not provide
enough pain relief. Due to the retrospective design of this study, the reason for not returning
within six months could not be determined. There are a number of reasons older patients may
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not return as soon as younger patients for a second injection including mobility, health insurance
and social support. Though it was not possible to collect information on mobility or details
regarding health insurance, social support might be measured using marital status as a surrogate.
Marital status was not associated with injection treatment effectiveness. However, other forms
of social support were not available for this study and may have affected the association. For
example, if younger patients have more support from family members other than spouses, they
may be more likely to receive help in returning for a second visit as compared to older patients.
Another consideration for the difference could be due to the small sample size, where
only a third of all patients were aged 70 and older (n=29). Future research studies may benefit
by focusing on this age group to better understand the differences in receipt of repeat injections.
A further consideration is the way in which patients were categorized. Patients categorized as
"not receiving a second injection within six months" (Table 2) included both patients who did
receive a second injection after six months (n=13) as well as patients who never received a
second injection at all (n=27). This approach effectively answers the question about whether a
patient returned for a second injection within six months or not, but it should be noted that the
comparison group contained a mixed sample. The analysis was repeated for patients who
required a second injection within 12 months and similar results were seen.
The study found that the amount of time patients may expect pain relief, as measured by
time elapsed between first and second injection, may vary by several patient characteristics
though none of these reached statistical signficance. In the entire cohort, patients did not seek a
second injection for an average of almost 5 months. Differences between groups by various
patient characteristics were not significant. However, only about two-thirds of the cohort had
received a second injection (n=65). It should be noted that more than half of all patients in this
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cohort were obese to morbidly obese and the vast majority were in the overweight, obese or
morbidly obese categories (87%). The large proportion of patients qualifying as morbidly obese
(13%) had an average of 5.2 months between injections, compared to approximately 3 months
for lower BMI patients, although this was not significant. The reasons for not returning sooner
could be similar to older patients, such as problems with mobility and social support.
Another goal of this study was to explore patient characteristics that may be related to
pain relief and return for a second injection. As described previously, the patient characteristics
noted as potential influences in this study are age and Body Mass Index. Though this study does
not have the power to detect statistically sound differences between patient groups, the results
contribute to the body of research building for injection treatment. The differences found will
inform power analyses for further research in these areas.
Another limitation of this study was the lack of information about LSS severity. Since
MRI records were only available for about one-third of the patients, sample power was
inadequate for assessing how LSS severity may have affected treatment. In a sub-analysis, VAS
pain scores were consistent with LSS severity, where baseline means were considerably higher in
more severe cases (7.3) versus milder cases (5.2). In addition, LSS severity was tested in the
adjusted logistic regression model, but did not show significance. It is not clear if a larger
sample would have yielded similar results. Therefore, it would benefit future research to collect
information on LSS severity to more adequately assess injection treatment effectiveness.
Lack of information about patients who did not receive a second injection within the
study data collection time period was another limitation. It is unclear if these patients received a
second injection after data collection was completed, received an injection elsewhere or never
received a second injection. Since nearly one-third of the study patients were considered
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uncensored in this study (27/92), it may be useful for future research to extend the follow-up
period to collect additional information on those lost to follow-up. However, in this study,
censored and uncensored patients were compared and their characteristics were similar. In
addition, all 27 patients were continued users of the UMass healthcare system, so it is unlikely
they received second injections at other institutions.
Further investigation is needed in this age group to determine why younger patients
return sooner than older patients. Both physical and mental differences could exist between the
two age groups, such as a larger desire for an active lifestyle in the younger group. In addition,
this cohort included only patients over age 60, but the vast majority ranged from overweight to
morbidly obese. The profile of patients over age 60 with lower back pain who seek injection
treatment is interesting and warrants further investigation, but is not within the scope ofthis
research. However, as with older patients, people with higher BMI's should be more carefully
examined in future research to determine the reasons a second injection is not sought as soon as
in lower BMI patients.
As the proportion of older people in the general population continues to increase over the
next two decades, clinicians wi11likely seek information about how to best treat their lower back
pain. If injection therapy continues to be the preferred treatment in this age group in the future,
further research is needed for clinicians to better understand how to achieve the best outcome.
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CHAPTER 3
Functional improvement after injection treatment in older adults
with lumbar sp",in..,a",l,-,s",t",en",o",s",i",-s _
INTRODUCTION
Lumbar spinal stenosis (LSS) is a common condition that causes pam in the lower
extremities and/or back. LSS is most often caused by degenerative changes in older adults,
resulting in compression of nerve roots and narrowing of the lumbar spinal canal. In 2004, thirty
percent of Americans 65 years and older reported symptoms of lower back pain '. Treatment to
alleviate pain has historically included both surgical and non-surgical approaches. Due to risks
associated with lumbar spinal surgery, especially in aging adults 17, many physicians and patients
choose non-surgical methods of treatment. One commonly recommended treatment to alleviate
symptoms for lumbar spinal stenosis is injection therapy, with medications containing steroids
and/or analgesics. As the population ages, complaints about back pain caused by LSS will likely
rise, and effective low-risk procedures to alleviate pain will be in increasing demand. However,
there is limited information about injection treatment in older adults diagnosed with LSS.
Studies published to date have included patients with diagnoses other than LSS, included a wide
range of ages, and used a number of different measurement tools for both pain and function 7-12,
22, Measurement of functional return following treatment has been particularly inconsistent in
previous literature. A wide variety of instruments, including surveys and walking tests have
been used to measure function in past studies. In this study, functional return has been examined
in adults age 60 and over using both a global physical health measurement tool (Short Form-
36/PCS) and a spine specific measurement tool (Oswestry Disability Index). Older patients
scheduled to receive a lumbar injection were prospectively enrolled and followed for three
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months after their initial injection. Questionnaires were completed at baseline, one month and
three months post injection to measure physical function.
METHODS
Patient Population
All patients 2: 60 years old, who had been diagnosed with lumbar spinal stenosis and were
scheduled to receive any injection for lower back pain at the Spine Center were eligible.
Potential study patients were identified by reviewing Injection Room schedules two weeks in
advance. Diagnosis of LSS was confirmed by the primary investigator using Magnetic
Resonance Imaging reports and clinical notes. Exclusion criteria were receipt of a previous
injection in the lumbar within the past 6 months; lumbar surgery within the past two years;
history of lumbar fracture, malignancy or infection; inability to provide informed consent due to
dementia or cognitive impairment; co-existing musculoskeletal conditions that would negate
functional improvement with injection (e.g., severe Parkinson's disease, or hemiparesis) or
amputation of any lower extremity. All patients who agreed to participate provided signed
consent forms and completed one general health questionnaire and one questionnaire specific to
back pain before their scheduled injections.
Approximately three weeks following baseline injection, patients were mailed one-month
follow-up questionnaires. If the questionnaires were not returned within two weeks, the
participants were contacted by phone. Two additional calls were made if the surveys were still
not returned. The process was repeated for the three month follow-up period. This study was
approved by the Institutional Review Board (IRB) at the University of Massachusetts Medical
School.
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Treatment
Epidural Steroid Injection Procedure:
Patients of two physiatrists were included in the study. One physiatrist administered
injections to 93.5% of patients (n=58). In the procedure room, the patient was placed in a prone
position. The skin over the intended interlaminar target site was marked and prepped in the usual
sterile fashion. The skin and subcutaneous tissue were anesthetized with 1% lidocaine mixed
with sodium bicarbonate 8.4% (10:1). The tip ofa 20-gauge, 3.5-inch Tuohy spinal needle was
advanced under intermittent fluoroscopic guidance towards the target. Loss of resistance with air
was used to identify the epidural space. After negative aspiration for blood and cerebrospinal
fluid, Isovue was injected to confirm epidural placement. Subsequently, 5 mL of injectate (I mL
Triamcinolone Acetonide (40 mg/mL) and 4 mL 0.5% preservative-free Xylocaine) was
administered. The needle was removed. (For multiple levels, 5 mL of injectate was distributed
equally between levels injected. For caudal injections, lOmL of injectate (I mL Triamcinolone
Acetonide (40 mgimL), 5 mL preservative-free normal saline, and 4 mL preservative-free 0.5%
Xylocaine) was slowly administered without resistance).
Outcome Measures
The primary outcome measures used for this study were the paper and pencil versions of
the Short Form-36 (SF-36 version 2)(Ware 1993) and the Oswestry Disability Index 23. SF-36
surveys were scored using Quality Metrics SF-36 scoring software by a research assistant.
Training to use the scoring software was given by the orthopedics department research
coordinator. Raw data from Oswestry surveys were entered into an ACCESS 20 database form
by the research assistant, then checked and scored after transfer into an EXCEL 24 spreadsheet by
the primary investigator. All survey scores were manually entered into an ACCESS database
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form by the research assistant and every fifth record was checked for accuracy by the primary
investigator.
Short Form-36 (SF-36)
The SF-36 Questionnaire is a multi-purpose 36-item questionnaire used to assess
functional health and well-being. It is one of the most frequently used questionnaires to assess
health related quality of life in patients with back pain 25. The SF-36 has been validated 26 and
compared to the Oswestry Disability Index in evaluating function in patients with lower back
pain in a 2006 study by Ferrer 27. It has been used in large-scale studies examining
musculoskeletal issues, including a prospective study by Zanoli examining 451 patients with
degenerative lumbar spine disorders 25. Also, the SF-36 was used by Vogt et ai., in the
evaluation of 5,995 men 65 years and older in the Osteoporotic Fractures in Men Study 28.
The questionnaire represents multiple indicators of health including eight components.
Four of these components relate to physical health and produce the measure Physical Component
Summary (PCS). The remaining four components relate to mental health and produce the Mental
Component Summary (MCS). In this study, two components were used; the PCS (as a primary
outcome) and the MCS (as a covariate). The PCS was presented as a global health measure of
function. Scores range from 0 (poor health) to 100 (excellent health).
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Oswestry Disability Index
The Oswestry Disability Index (ODI) is a one ofthe most commonly used tools for
measuring disease-specific functional ability in patients with spinal disorders. It is considered
the "gold standard" for evaluating function in patients with low back pain 29. The ODI was
presented as a spine-specific measure of function. Scores range from 0 (excellent function) to
100 (poor function).
Covariates Measured
To assess physical attributes that could affect the response to treatment for pain and
function, information about gender, age, body mass index (BMI), hip or knee replacement
surgery history and co-morbidities was collected. Co-morbidities were scored using the
Charlson Comorbidity Index (CCI) 30. The CCI includes 19 co-morbidities, selected based on
their association with mortality. It includes conditions related to cancer, diabetes, heart disease,
liver disease, renal disease, chronic pulmonary disease and others. Following retrieval of
diagnosis histories using electronic medical files, the CCI questionnaire was completed by the
principal investigator. Results were verified by a dedicated orthopedic research resident.
Medical records were also used to collect information on patient history of hip or knee
replacement surgery to adjust for other lower extremity arthritic changes common in this age
group and were included in the analysis.
To adjust for other pain control medications that may interfere with injection treatment,
Information about narcotic use was also collected. Ethnicity information was not consistently
reported in patient files and thus was not included in the analysis.
In this study, all variables were collected and analyzed as moderators (pre-treatment).
However, consideration was given to two variables that may have had an effect as mediators
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(post-treatment); narcotics use and baseline emotional health. As a pain management
medication, narcotics use could have had an effect on pain receptors, but not on inflammation.
Since narcotics use was not collected after treatment, this was a relationship that was not possible
to consider in this analysis. Baseline emotional health may also have had an effect as a mediator
as well as a moderator. However, past literature in musculoskeletal research suggests that
emotional health is a moderator, that dampens the self efficacy leading to function. Therefore,
this variable was collected and analyzed as a moderator in this study.
Data Collection
Demographic information was collected by the primary investigator using hospital
administrative data and medical records. Survey scoring was accomplished using Quality
Metrics scoring software for the SF-36 survey, and EXCEL for the Oswestry Disability Index. A
data entry program was developed using ACCESS and data were entered by a research assistant
and the primary investigator. Data entry was verified by reviewing every fifth record and no
errors were found.
Analytic Plan
Descriptive statistics summarize patient characteristics such as gender, baseline
emotional status (MCS), BMI, co-morbidities, narcotic use and history of total hip or knee
replacement surgery (THKR). See Table I. Baseline MCS and BMI were transformed to
categorical variables. For categorical variables (gender, baseline MCS, BMI, co-morbidities,
narcotics and THKR), numbers and percentages were presented. Age was presented as a
continuous variable with mean, standard deviation and range. T-tests compared physical
function between baseline and one month and between baseline and three months for each
patient characteristic category (i.e. gender, age 60-69, age 70+, etc.). See Tables 2 and 3.
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Differences in function score changes among patient categories (i.e. BMI groups) were
assessed using analysis of variance tests. Significant variables in the univariate analysis were
entered into the multivariate model. Change in function was examined in a series of linear
mixed effects models. The mixed effects model assumes that repeated measurements in the
same individual are not independent and allows individuals to have unequal numbers of
observations. In this study, the outcome measure was collected at three timepoints, and some
outcome data and covariate information were missing. The linear mixed effects model
compensated for these missing data. The fixed effects portion of the model consisted ofthe
variables that were significant in the univariate analysis (analysis of variance). The random
effects portion of the model consisted of a random intercept only. This term accounts for
between-subject variation. For example, in this study, baseline measurements of function were
analyzed as separate values for each patient, rather than as a mean. Unconditional models (fixed
time) and conditional models (fixed time, BMI, MCS, age, gender) were compared to determine
changes in variance after the addition of variables to the model. Akaike's information criterion
was used to assess goodness-of-fit between the models.
All variables in the analysis were also tested for an interaction with time (age, gender,
baseline emotional health, BMI, co-morbidities, narcotic use, hip or knee replacement).
Likelihood ratio tests were used to compare models with and without time/variable interactions.
Test results producing significant p-values (p<.05) indicated time interactions were present and
were included in the final model. By adding variables into the model individually, potential
interactions between variables were also evaluated and significant interactions were included in
the final model. Model assumptions of linearity, normality, independence of errors, and
homoscedasticity of errors were examined graphically and analytically and were adequately met.
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ACCESS files were exported using StataTransfer 21 for statistical analyses using Intercooled
STATA 9.0 21. All available data from all participants were used, as long as at least one follow-
up survey was returned.
RESULTS
Eighty-six patients were initially enrolled and completed baseline SF-36 and Oswestry
Disability Index questionnaires administered by the primary investigator from January I, 2008 to
July I, 2008. All patients signed study consent forms approved by the IRB. Participants were
followed at one month and at three months following baseline (Figure 1). At one month, 4
participants withdrew from the study, 2 were dropped from the study (for having a second
injection before follow-up (n=l) or for never having the first injection (n=I), 4 did not return the
first follow-up surveys, 7 received nerve blocks, 6 received radiofrequency denervation and I
died. Ofthe initial 86 participants, 62 were still enrolled after one month, 61 returned SF-36
surveys and 61 returned Oswestry surveys. At three months, 1 withdrew from the study and 4
did not return the second follow-up surveys. At the end ofthe second follow-up period, 61
participants were still enrolled and 56 returned three-month surveys. All patients remaining in
the study received epidural steroid injections.
The mean age of participants was 74 (SD=8.1, range 60 to 90), 68% were female, 60%
had high baseline emotional health (MCS::::50) and 44% were obese to morbidly obese
(BMI::::50). See Table I.
Figure 3.1: Patient enrollment flow
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86 patients enrolled and completed
baseline surveys
(January 1, Z008 - July 1, Z008)
4 withdrew from the study
1 month follow-up 1 received Znd injection before 1 month1 never received baseline injection
4 did not return one-month surveys
6Z patients still enrolled 7 received nerve blocks
62 returned SF-36 one-month surveys 6 received radiofrequency denervation
61 returned Oswestry one-month surveys 1 died
3 months follow-up 1 withdrew from the study
4 did not return three-month surveys
61 patients still enrolled
56 returned three-month surveys
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Change in SF-36 PCS and Oswestry scores were tabulated in Tables 2 and 3. Significant
improvement was found at one month follow-up in both survey results. SF-36 PCS scores
showed a 3.3 point improvement (SD=6.3; p:S .05) and the aD! showed a 3 point improvement
(SD=I1.2; p < .05). Patient characteristics showing significant improvement (p < .05) at one
month were age 60-69, were female, had high baseline emotional status (MCS~50), had normal
weight, had no co-morbidities or had never had hip or knee replacement surgery. No significant
improvement was found at three months follow-up in either PCS (p=.09) or aD! (p=.27). Means
of function scores for both PCS and ODr are presented in Figure 2.
Higher baseline emotional status was the only characteristic that was associated with
improvement in function at three months, where PCS scores showed a 3.6 point improvement
over baseline (SD=7.9; p < .05). A one-way analysis of variance model (ANOVA) was used to
compare PCS and ODr score means between group categories (i.e. male vs. female) at both one
and three months (Tables 2 and 3). aD! scores differed significantly (p < .05) between age, BMr
and co-morbidity categories. PCS differed significantly between baseline emotional status
categories. Function score means for both PCS and ODr by baseline emotional status categories
are presented in Figure 3.
Results from a mixed effects model analysis are presented in Tables 4 and 5. Only
variables found to be significant in the univariate (unadjusted) analysis (ANOVA) and identified
variable interactions were included in the multivariate (adjusted) analysis. To account for small
sample size, body mass index categories were collapsed to two categories, obese and non-obese.
Co-morbidities were also collapsed from four categories to two categories (co-morbidities versus
no co-morbidities). The PCS scores among baseline emotional health groups showed an
interaction with time. Therefore, an interaction term (baseline MCS/time) was also included in
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the model. Using PCS scores, comparison of covariance estimates of the conditional model
showed a small improvement in goodness of fit (0.18%, of additional variance explained for
emotional health; likelihood ratio test, p-value<.05) when compared to the unconditional model
(time alone). Usng Oswestry scores, comparison of covariance estimates of the conditional
model showed a small improvement in goodness of fit (2.1 %, of additional variance explained
for emotional health; likelihood ratio test, p-value<.05) when compared to the unconditional
model (time alone).
After analysis, the only variable showing significance was baseline emotional health.
Function scores were significantly improved at both timepoints. In patients with high baseline
emotional health, PCS function scores increased by 6.1 points from baseline to one month and by
4.6 points from baseline to three months, as compared to patients with low emotional health.
Changes in the Oswestry also showed improvement for patients with high baseline emotional
health, but did not show an interaction with time. Oswestry scores improved by 17.8 points over
the three months follow-up period for patients with high baseline emotional health (MCS 2': 50).
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Table 3.1: Patient characteristics at baseline
Characteristic N % SF-36 Oswestry
PCS Baseline
Baseline-Mean-t~m)
Mean
(SD)
Total 65 100 28.2 (7.6) 50.6 (14.0)
Age
Mean 74
SD 8.1
Range 60-
90
Gender
Male 21 32 28.5 45.6 (11.3)
Female 44 68 28.1 58.0 (14.7)
Baseline emotional status
(SF-36/MCS)
Low« 50) 26 40 28.5 60.2 (12.9)
- High (2:50) 39 60 28.1 44.2 (10.8)
Body Mass Index (kg/m2)
Normal Weight «25) 14 25 29.2 49.8 (13.2)
Overweight (25-29) 17 31 28.8 48.4 (17.1)
Obese (30-34.9) 12 22 26.0 50.1 (15.3)
Morbidly Obese (>35) 12 22 25.4 55.7 (12.1)
Number of Co-morbidities
0 31 48 29.1 51.1 (14.7)
I 10 15 21.3 50.2 (11.0)
2 11 17 29.4 49.0 (16.2)
2:3 13 20 30.5 51.1 (13.9)
Narcotic Use
Yes 16 30 26.6 58.9 (12.8)
No 38 70 28.4 47.4 (13.3)
Hip or Knee Replacement
Yes 11 20 27.1 49.6 (17.4)
No 43 80 28.0 51.1 (13.3)
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Table 3.2: Change in SF-36 PCS from baseline to one month and baseline to three months.
Patient characteristics Baseline to 1 Baseline to 3
month months
_____________----'dchwawn,ge change"-:::-:::-:- _
(mean, SD) p (mean, SD)
N=61 N=56
3.3 (6.3) <.05 1.6 (7.3)
*
.09
<.05
<.05
.12
<.05
.18
.30
.55
.52
<.05
.21
.30
.20
.78
<.05
.69
.80
.36
.29
0.3 (5.8)
9.2 (6.7)
-1.2 (9.3)
.38 (4.8)
-1.2 (7.2)
1.5 (8.8)
5.8 (6.6)
3.2 (6.7)
*
.09 2.5(8.1)
<.05 1.2 (6.9)
<.05 1.9 (8.0)
<.05 1.5 (6.9)
<.05
<.05
.10
.11
.88 -1.6 (4.6)
<.05 3.6 (7.9)
<.05
<.05
<.05
.80
<.05 1.6 (6.6)
<.05 1.6 (804)
.16 (5.3)
5.6 (5.9)
2.8 (6.7)
3.6 (6.1)
3.3 (6.0)
6.0 (6.2)
4.9 (6.2)
4.7 (6.5)
3.8 (604)
3.1 (6.3)
3.9 (4.8)
004 (6.9)
6.9 (SA)
404 (7.9)
3.7 (6.5)
4.1 (5.9)
Total (n=56)
Gender
Male
Female
Age
60-69
70+
Baseline Emotional
Status
(SF-36/MCS)
< 50
2: 50
BMI
Normal weight
Overweight
Obese
Morbidly obese
Comorbidities
o
1
2
2:3
Narcotic Use
Yes
No
Hip or Knee
Replacement Surgery
Yes 4.2 (5.0) <.05 3.2 (8.0)
No 3.9 (604) <.05 1.2 (7.8)
P-values represent Hest results comparing baseline and follow-up scores;
One month change in pain ~ I month SF-36 PCS score - baseline SF-36 PCS score;
Three month change in pain ~ 3 month SF-36 PCS score - baseline SF-36 PCS score;
• One way ANOVA p-values :s .05 comparing variable categories (i.e. male vs. female)
Table 3.3: Change in Oswestry scores from baseline to one month and baseline to three
months.
Baseline to 1 Baseline to 3
month-change months-change
Patient (mean, SD) (mean, SD)
characteristics N=62 p N=56 P
Total -3,0 (11.2) <,OS -1.4 (9,5) ,27
Gender
Male -0,9 (10,8) ,70 -,79 (8,2) ,67
Female -3,9 (11.5) <.05 -1.7 (10,2) .30
Age *
60-69 -6,8 (12,9) <.05 -1.9 (10,3) .41
70+ -0,8 (9,7) ,59 -1.2 (9.2) .45
Baseline Emotional
Status (SF-
36/MCS)
< 50 -1.2 (11.1) ,59 -1.1 (8.4) .55
2: 50 -4.4 (11.3) <.05 -1.6 (10.2) .35
BMI *
Normal weight -5.8 (9.6) <,OS -2,5 (12.1) .46
Overweight 3.4(10.4) .20 -,66 (8,0) ,76
Obese -2.4 (6.5) ,24 .97 (9.6) ,73
Morbidly obese -6.4 (12,6) .12 -3.1 (7,8) ,29
Comorbidities *t
0 -6,6 (12,6) <.05 -3.4 (8,8) ,06
1 -1.4 (9.2) ,65 0,6 (6.6) ,78
2 -0,9 (8.6) ,74 4.0 (11,8) ,30
2:3 2,0 (9,8) .48 -3,7 (9,8) ,24
Narcotic Use
Yes -6,9 (11,8) <,OS -4,2 (7.8) ,65
No -3.4 (10.9) ,06 .17 (9,9) .23
Hip or Knee
Replacement
Surgery
Yes -2,7 (10,5) .40 1.3 (9,1) .40
No -4,9 (11.4) <.05 -1.9 (9,6) ,96
P-values represent !-test results comparing baseline and follow-up scores;
1 month change in pain ~ baseline Oswestry - 1 month Oswestry (62 respondents);
3 months change in pain ~ baseline Oswestry - 3 month Oswestry score (56 respondents);
* One way ANOVA p-values S .05 comparing variable categories (Le. male vs. female)
t Co-morbidities significant when analyzed as yes/no
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0.24 (-2.85, 3.33)
-1.32 (-4.70, 2.04)
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Figure 3.2: Mean function scores at baseline, 1 month and 3 months
.Oswestry PCS
Note: Better function is indicated by lower Oswestry scores and higher PCS scores
Table 3.4: Predictors of change in function (PCS) over 3 months (multivariable analysis).
Patient Characteristics PCS
~-----::---::-::c:::::-:-::-::::------------'P(95%CI)
Baseline MCS «50)
Change from baseline to 1 month
Change from baseline to 3 months
Baseline MCS (2:50)
Change from baseline to 1 month 6.11 (3.60, 8.63) *
Change from baseline to 3 months 4.60 (2.02, 7.18) *
Based on mixed effects model analysis; • p<.05; Adjusted for age, BMI (obese vs. non-obese). gender and
baseline MCS/time interaction.
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Table 3.5: Predictors of change in function (Oswestry) over 3 months (multivariable
analysis).
Patient Characteristics Oswestry
---==================iP:f(9~5°~Yoe~Ilt)===------------
Baseline MCS «50) referent
Baseline MCS (:=:50) -17.8 (-23.60, -11.91) *
BMI (obese vs. non-obese) 0.08 (-5.46, 5.62)
Gender (males vs. females) -3.64 (9.99,2.70)
Age (60-69y vs. 70+y) 4.63 (-0.94, 10.2)
Co-morbidities (yes vs. no) 3.92 (-1.58, 9.43)
Based on mixed effects model analysis; *p<.05; Adjusted for age, BMI (obese vs.non-obese), comorbidities (YIN),
and gender.
Figure 3.3: Mean function scores at baseline, 1 month and 3 months by baseline emotional
health categories
Oswestry PCS
DISCUSSION
This study showed that in patients over age 60 with lumbar spinal stenosis, injection
treatment was associated with increase in function at both one and three months after treatment.
Spine specific functional return, as measured by the Oswestry Disability Index, was significantly
associated with high baseline emotional health at both one and three months. Age, BMI and the
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coexistence of co-morbidities were also possible predictors of functional return but were not
significant in the adjusted analysis.
Previous literature has shown injection treatment to be associated with reducing pain and
increasing function in patients with lumbar spinal stenosis (Botwin 2003, Barre, Cooper,
Igarashi, Ng, Rivest, Fukusaki). The results ofthis study support those findings, but more
specifically, within older adults. In addition, high baseline emotional status has been associated
with an increase in function in previous studies concerning treatment for other musculoskeletal
disorders including knee replacement surgery (Ayers) and hip replacement surgery (Bischoff-
Ferrari). Within older adults receiving hip surgery, good mental health status has also been
associated with increased function (Travis). This study supports these findings as well. A
positive response to musculoskeletal treatment in older patients with good baseline emotional
health may be due to a greater adherence to post-treatment rehabilitation, a stronger social
support network or a healthier lifestyle.
Response to injection treatment has not been well studied in older adults. However, this
study showed a more positive response to treatment in patients age 60 to 69 compared to patients
70 and older one month after treatment. In a previous study examining hip replacement surgery
(Bischoff-Farrari), age was not considered a significant factor for functional improvement.
However, several physical problems commonly associated with geriatric patients including
history of falls, decreased balance, vision and hearing were significant correlates of reduced
function after hip surgery. Thus, these physical limitations could likely have influenced the
response of those in the older patient group in our study.
Absence of co-morbidities was associated with greater functional gain following
treatment in this study. This is consistent with previous research where the presence/absence of
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co-morbidities was associated with variations in functional improvement 24. The presence and
number of co-morbidities in patients receiving treatment may be particularly important in older
adults. This group may likely be more vulnerable to co-existing illnesses and therefore respond
to treatment differently. For example, increased medication use, reduced activity and reduced
immunity to common illnesses could affect response to injection treatment for lower back pain.
The primary limitations of this study were relatively small sample size and a short
follow-up period. However, sample size was adequate to determine that significant functional
improvement did occur following treatment in older patients. Future research should include
longer follow-up periods as well as larger study sample sizes to further explore this relationship
as well as age differences, the co-existence of co-morbidities and BMI.
Additional limitations include measurement of co-morbidities and stenosis severity.
Measurement of co-morbidities was accomplished using the Charleson Comorbidity Index. This
tool did not include minor conditions that may have had impact on treatment response. As this
study showed a potential relationship between co-morbidities and functional gain, future studies
may use a more comprehensive tool to measure co-morbid conditions, especially in older adults.
Stenosis severity has been documented in previous studies using Magnetic Resonance Imaging
(MRI) films for measurement 25-27. Films were unavailable at the time ofthis study, and severity
was not documented in the majority of patients. However, MRI reports were available and
reviewed to confirm diagnosis. Reports that indicated disc related LSS as being the primary
diagnosis were not included in the study. Future studies should verify access to films upon
subject enrollment to ensure collection of severity information.
Another limitation of this study is the absence of a comparison group. The ideal
comparison group for this treatment would be the use of a placebo. Due to the invasive nature of
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injection treatment, and the ethical considerations of subjecting patients to a potentially useless
treatment, a randomized control design would be difficult if not impossible. Another comparison
group could consist of patients who received another treatment, such as surgery. Again,
randomizing patients to an even more invasive procedure such as surgery would also pose many
problems. Lastly, another comparison group could have consisted of patients who did not
receive treatment. However, this study consisted of patients with lumbar spinal stenosis
primarily caused by degenerative arthritis. As degenerative arthritis is a condition that does not
improve on its own, we would expect a group without treatment to remain unchanged over time.
Selection bias was also a potential limitation ofthis study. Though consideration of this
potential problem was addressed in study design (by enrolling all patients who met study
inclusion criteria and agreed to participate), patients who chose to participate may have had
different characteristics from those who refused. However, the vast majority (96%) of patients
approached agreed to participate and those who did not choose to participate were similar in age
and gender distribution.
The main purpose of this study was to quantify the amount of functional return following
injection treatment in older adults. Significant functional return was observed at one month and
approached significance at three months. The second purpose was to explore baseline patient
characteristics that may have influenced response to treatment. Baseline emotional health
emerged as a significant patient characteristic at both follow-up periods. This association is
supported by previous related research and should be included in future studies examining the
effectiveness of injections in older adults. Iflow baseline emotional status is a risk factor for
poor response to treatment, physicians may choose to evaluate the emotional health oftheir older
patients before treatment begins.
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CHAPTER 4
The association between injection treatment and back pain
--------------eaused-by-Iumbar-spinal-stenosis-in-older-adults--------------
INTRODUCTION
Lower back pain is one of the most common health-related complaints in the adult
population. Thirty percent of Americans 65 years and older reported symptoms of lower back
pain in 2004 '. With an aging population, the proportion of people over the age of 65 is expected
to reach 20% by the year 2030. Because of this increase in older adults, lumbar spinal stenosis
associated with arthritic changes will also likely increase. In older adults, lower back pain is
most often caused by degenerative lumbar spinal stenosis. Stenosis is the narrowing of the spinal
canal, causing pressure on the nerve roots and is frequently treated surgically. Lumbar spinal
stenosis is one of the most common reasons for back surgery in patients 65 years and older 2.
However, risks associated with surgery increase with age 3-5 and older patients may choose non-
surgical treatment for their lower back pain, including injection treatment.
Injection treatment, usually consisting of anti-inflammatory medications and analgesics,
has improved since the mid-1990's when fluoroscopic guidance was developed 6. Information
about injection treatment for lower back pain is limited, especially in the older population. An
extensive review of published literature regarding injection treatment revealed a paucity of
information about older adults diagnosed with lumbar spinal stenosis 6-13. In this study, pain
relief following injection treatment has been examined in patients over age 60, diagnosed with
lumbar spinal stenosis primarily caused by degenerative changes. Variations in pain relief
according to patient attributes were also assessed. To our knowledge, such results have not been
reported in the literature.
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METHODS
Patient POI!-"u"la...,t"io"'n'-- _
All patients 2: 60 years old, who had been diagnosed with lumbar spinal stenosis and were
scheduled to receive any lumbar injection for lower back pain at the Spine Center were eligible
for review. Diagnosis ofLSS was confirmed using Magnetic Resonance Imaging reports and
clinical notes. Potential study patients were identified by reviewing Injection Room schedules
two weeks in advance. Exclusion criteria were receipt of a previous injection in the lumbar
region within the past 6 months; lumbar surgery within the past two years; history oflumbar
fracture; acute disc herniation; malignancy or infection; inability to provide informed consent
due to dementia or cognitive impairment; co-existing musculoskeletal conditions that would
negate functional improvement with injection (e.g., severe Parkinson disease, or hemiparesis) or
amputation of any lower extremity. All patients who agreed to participate provided signed
consent forms and completed one general health questionnaire and one questionnaire specific to
back pain before their scheduled injections. Eighty-nine patients were approached to participate
in the study and 86 (96%) agreed and completed baseline questionnaires.
Approximately three weeks following baseline injection, patients were mailed one-month
follow-up questionnaires. If the questionnaires were not returned within 2 weeks, the
participants were contacted by phone. Two additional calls were made if the surveys were still
not returned. The process was repeated for the three month follow-up period.
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Treatment
Epidural Steroid Injection Procedure:
Patients of two physiatrists were included in the study. One physiatrist administered
injections to 93.5% of patients (n=58). In the procedure room, the patient was placed in a prone
position. The skin over the intended interlaminar target site was marked and prepped in the usual
sterile fashion. The skin and subcutaneous tissue were anesthetized with I% lidocaine mixed
with sodium bicarbonate 8.4% (10:1). The tip ofa 20-gauge, 3.5-inch Tuohy spinal needle was
advanced under intermittent fluoroscopic guidance towards the target. Loss of resistance with air
was used to identify the epidural space. After negative aspiration for blood and cerebrospinal
fluid, Isovue was injected to confirm epidural placement. Subsequently, 5 mL of injectate (I mL
Triamcinolone Acetonide (40 mg/mL) and 4 mL 0.5% preservative-free Xylocaine) was
administered. The needle was removed. (For multiple levels, 5 mL of injectate was distributed
equally between levels injected. For caudal injections, 10mL of injectate (I mL Triamcinolone
Acetonide (40 mg/mL), 5 mL preservative-free normal saline, and 4 mL preservative-free 0.5%
Xylocaine) was slowly administered without resistance).
Outcome Measure
The primary outcome measure used for this study was the paper and pencil version of the
Short Form-36 (SF-36 version 2) 31. The SF-36 Questionnaire is a multi-purpose 36-item
questionnaire used to assess functional health and well-being of adults. It is one of the most
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frequently used questionnaires to assess health related quality of life in patients with back pain 25
and has been used in large-scale studies examining musculoskeletal issues, including a
prospective study by Zanoli examining 451 patients with degenerative lumbar spine disorders 25.
The SF-36 was also used by Vogt et aI., in the evaluation of 5,995 men 65 years and older in the
Osteoporotic Fractures in Men Study 28.
The questionnaire represents multiple indicators of health including eight components.
Four of these components relate to physical health and produce the measure Physical Component
Summary (PCS). The remaining four components relate to mental health and produce the Mental
Component Summary (MCS). In this study, two components were used; the Pain sub-score of
the PCS (as a primary outcome for long-term pain) and the MCS (as a covariate).
The SF-36 surveys were scored using Quality Metrics SF-36 scoring software by a
research assistant. Training to use the scoring software was given by the orthopedics department
research coordinator. All survey scores were manually entered into an ACCESS database form
by the research assistant and every fifth record was checked for accuracy by the primary
investigator.
Covariates Measured
To assess physical attributes that could affect the response to treatment for pain
and function, information about gender, age, body mass index (8MI), hip or knee replacement
surgery history and co-morbidities was collected. Co-morbidities were scored using the
Charlson Comorbidity Index (CCI) 30. The CCI includes 19 co-morbidities, selected based on
their association with mortality. It includes conditions related to cancer, diabetes, heart disease,
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liver disease, renal disease, chronic pulmonary disease and others. Following retrieval of
diagnosis histories using electronic medical files, medical conditions relevant to Charlson Index
were recorded and the Index was computed by the first author. Results were verified by a
dedicated orthopedic research resident. Medical records were also used to collect information on
patient history of hip or knee replacement surgery to adjust for other lower extremity arthritic
changes common in this age group and were included in the analysis.
Magnetic Resonance Imaging reports were reviewed for information about lumbar spinal
stenosis diagnosis. Reports that indicated acute disc herniation in the lumbar region as being the
primary diagnosis were not included in the study. When available, images were reviewed to
determine LSS severity. A mid sagittal diameter of 2': 13 was classified as "mild", lito 12 was
classified as "moderate" and :s 11 was classified as "severe 32,33.
To adjust for other pain control medications that may interfere with injection treatment,
information about narcotic use was also collected. Medication lists were reviewed using
electronic records and noted as "yes" or "no" regardless of dosage of medications. Narcotic use
was defined as being used or reported within three months of baseline injection,
To adjust for other lower extremity joint arthritis common in this age group, information
was collected on history of total hip or knee replacement surgery using medical records.
Demographic and anthropometric information was collected using hospital administrative data
and medical records. Information was also collected on body mass index (BMI) and
demographic variables (gender, age and race). Information about race was not consistently
reported in patient files and was not included in the analysis.
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Data Collection
Demographic information was collected using hospital administrative data and medical
records. Survey scoring was accomplished using Quality Metrics scoring software for the SF-36
survey. A standard was created and a corresponding data management program was developed
using Microsoft ACCESS 24. Data collected on paper forms were entered by a trained research
assistant and the first author. Quality of data entry was verified by reviewing every fifth record.
ACCESS files were then exported using StataTransfer. All statistical analyses were completed
using Intercooled STATA SE 9.0 21.
Analytic Plan
Descriptive statistics summarize patient characteristics such as gender, baseline
emotional status (MCS), BMI, co-morbidities, narcotic use and history of total hip or knee
replacement surgery (THKR). See Table 1. Baseline MCS and BMI were transformed to
categorical variables. For categorical variables (gender, baseline MCS, BMI, co-morbidities,
narcotics and THKR), numbers and percentages were presented. Age was presented as a
continuous variable with mean, standard deviation and range. T-tests compared physical
function between baseline and one month and between baseline and three months for each
patient characteristic category (i.e. gender, age 60-69, age 70+, etc.). See Table 2. Differences
in Pain score changes among patient categories (i.e. BMI groups) were assessed using analysis of
variance tests. Significant variables in the univariate analysis were entered into a multiple
regression model. Change in pain was examined in a series of linear mixed effects models. The
mixed effects model assumes that repeated measurements in the same individual are not
independent and allows individuals to have unequal numbers of observations. In this study, the
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outcome measure included function at baseline, I month and 3 months and the covariates
included MCS,BMI, gender, age and co-morbidities). The outcome measure was collected at
three timepoints, and some of both outcome data and covariate information were missing. The
fixed effects portion of the model consisted of the variables that were significant in the univariate
analysis (analysis of variance). Patient level intercepts were modeled as random effects. This
term accounts for between-subject variation. For example, in this study, baseline measurements
of pain were analyzed as separate values for each patient, rather than as a mean. Unconditional
models (fixed time) and conditional models (fixed time, BMI, MCS, age, gender) were compared
to determine changes in variance after the addition of variables to the model. Akaike's
information criterion was used to assess goodness-of-fit between the models.
All variables in the analysis were also tested for an interaction with time (age, gender,
baseline emotional health, BMI, co-morbidities, narcotic use, hip or knee replacement).
Likelihood ratio tests were used to compare models with and without time/variable interactions.
Test results producing significant p-values (p<.05) indicated time interactions were present and
were included in the final model. By adding variables into the model individually, potential
interactions between variables were also evaluated and significant interactions were included in
the final model. Model assumptions of linearity, normality, independence of errors, and
homoscedasticity of errors were examined graphically and analytically and were adequately met.
ACCESS files were exported using StataTransfer 19 for statistical analyses using Intercooled
STATA 9.0 19. All available data from all participants were used, as long as at least one follow-
up survey was returned.
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RESULTS
_______-'Eai.glnx-six patients were initiallx enrolled and completed baseline SF-36 questionnaires
administered by the first author from January 1,2008 to July I, 2008. All patients signed study
consent forms approved by the IRB. Participants were followed at one month and at three
months following baseline injection (Figure I). At one month, 4 participants withdrew from the
study, 2 were dropped from the study (for having a second injection before follow-up (n=l) or
for never having the first injection (n=I), 4 did not return the first follow-up surveys, 7 received
nerve blocks, 6 received radiofrequency denervation and I died. Of the initial 86 participants, 62
were still enrolled after one month and 62 returned SF-36 surveys. At three months, I withdrew
from the study and 4 did not return the second follow-up surveys. At the end of the second
follow-up period, 61 participants were still enrolled and 56 returned three-month surveys. All
patients remaining in the study received epidural steroid injections.
Patient characteristics including gender, emotional status (MCS), BMI, co-morbidities,
narcotic use and history of total hip or knee replacement surgery (THKR) are summarized and
presented in Table I. The mean age of participants was 74 (SD=8.1, range 60 to 90), 68% were
female, 60% had high emotional health (MCS~50) and 44% were obese to morbidly obese
(BMI~50). Baseline scores differed significantly by patient characteristics including baseline
emotional health and body mass index.
Figure 4.1: Patient enrollment.
86 patients enrolled and completed
baseline surveys
(January 1, 2008 - July 1, 2008)
4 withdrew from the study
1 month tallow-up 1 received 2"d injection before 1 month
1 never received baseline injection
4 did not return one-month surveys
62 patients still enrolled 7 received nerve blocks
62 returned SF-36 one-month surveys 6 received radiofrequency denervation
3 months tallow-up 1 withdrew from the study
4 did not return three-month surveys
61 patients still enrolled
56 returned three-month surveys
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Table 4.1: Patient characteristics at baseline
Characteristic N % SF-36 Pain Score
Baseline
Mean (SD)
27.4 (1.7)
28.8 (14.2)
26.7 (13.3)
21.3 (10.5)
31.4 (13.9)
28.5 (13.2)
26.4 (14.0)
30.8 (16.4)
27.6 (7.7)
28.0 (14.7)
22.3 (12.3)
30.7 (13.4)
26.9 (11.9)
22.1 (12.6)
29.4 (14.1)
32
68
21
26
18
18
40
60
48
15
17
20
25
58
10065
21
44
26
39
14
17
12
12
16
38
31
10
11
13
74
8.1
60-90
Total
Age
Mean
SD
Range
Gender
Male
Female
SF-36/MCS *
Low « 50)
High (2':50)
Body Mass Index
Normal Weight «25)
Overweight (25-30)
Obese (30-34.9)
Morbidly Obese (>35)
Comorbidities *
o
I
2
2':3
Narcotic Use *
Yes
No
Hip or Knee Replacement
Yes II 17 30.2(15.8)
No 43 66 26.5 (13.6)
Note: Mean SF-36 Pain score for the general population - 75.2 (SD-23.7) "
Baseline scores between group categories compared: • p<.05 (t-test); •• p<.05 (chi-square)
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Figure 4.2: Mean Pain scores at baseline, 1 month and 3 months
Changes in SF-36 Pain scores at one and three months were tabulated overall and by
patient characteristics in Table 2. Overall, significant improvement was found at both one month
and three months follow-up. SF-36 Pain scores showed a 14.1 (p<.05; 95% CI: 9.5, 18.7) point
reduction in pain at one month and an 8.3 (p<.05; 95% CI:4.0, 12.6) point reduction in pain at
three months. Significant differences (p<.05) in Pain score changes from baseline to one month
were found between BMI and emotional status categories. Baseline, one month and three month
means of Pain scores are presented in Figure 2.
Results from a linear mixed effects model analysis are presented in Table 3. Variables
found to have significantly different Pain score changes at either one or three months were
included in the analysis (BMI and MCS) as well as gender and age. No variable interactions or
interactions with time were found or included. To account for small sample size, body mass
index categories were collapsed to two categories, obese (BMI<30kg/m2) and non-obese
(BMI2:30kg/m2). Comparison of covariance estimates of the conditional model showed a modest
improvement in goodness of fit (0.69%,0.93%,0.79% and 0.64% of additional variance
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explained for emotional health, BMI, age and gender; p-value<.05) when compared to the
unconditional model (time alone).
The only variables showing significance were baseline emotional health and body mass
index. Pain scores were significantly improved for patients with high baseline emotional health
and for patients who were obese. In patients with high baseline emotional health, Pain scores
improved by 14.1 (p<.05; 95%CI 6.9, 21.3) points over three months, as compared to patients
with low baseline emotional health. In patients who were obese, Pain scores improved by 7.9
(p<.05: 95% CI; 1.0,14.8) points over three months, as compared to patients who were non-
obese. Mean Pain scores at baseline, one month and three months by emotional health status and
by BMI status are presented in Figures 3 and 4.
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Table 4.2: Change in SF-36 Pain scores from baseline to one month and baseline to three
months.
p
Patient characteristics SF-36 Pain change SF-36 Pain change
----------------BlTa""'s"'eTIlin=-e;c--------nBaseli;nnoe------------
to 1 month to 3 months
mean (SD) mean (SD)
N=61 P N=56
14.1 (9.5, 18.7) <.05 8.3 (4.0, 12.6)
<.05
<.05
<.05
<.05
<.05
0.43
<.05
9.4 (4.0, 14.7)
7.7 (1.8, 13.7)
3.9 (-6.8,14.5)
9.1 (3.6, 14.5)
7.6 (-0.12, 15.3)
8.7 (3.4, 14.0)
8.1 (3.5, 12.7) <.05
8.4 (2.0, 14.8) <.05
3.9 (-6.6, 14.4) 0.44
6.7 (-0.68,14.1) 0.07
7.9 (-5.2, 21.0) 0.21
14.8 (7.0, 22.5) <.05
10.7 (3.6,17.7) <.05
6.7 (0.43, 13.0) <.05
*
7.0 (1.3, 12.7) <.05
17.9 (6.4, 29.4) <.05
-1.2 (-12.9, 10.5) 0.82
11.2 (0.23, 22.1) <.05
<.05
<.05
*
<.05
<.05
**
<.05
<.05
<.05
<.05
<.05
<.05
<.05
<.05
<.05
0.66
<.05
<.05
16.2 (7.7, 24.7)
12.8 (7.2, 18.3)
10.9 (2.7,19.0)
15.4 (9.7, 21.1)
10.9 (5.3,16.5)
18.2 (3.7, 32.7)
15.5 (2.4,28.6)
17.2(2.8,31.5)
14.8 (5.9, 23.7)
13.2 (7.4, 18.9)
15.3 (7.6,23.0)
1.4 (-5.3, 8.2)
19.6 (7.1, 32.1)
19.9 (1.32, 38.5)
9.5 (3.9, 15.0)
17.3 (10.5, 24.1)
o
1
2
~3
Hip or Knee
Replacement
Yes 11.0 (-4.9, 26.8) 0.16
No 14.4 (9.8,19.0) <.05
Total (n)
Gender
Male
Female
Age
60-70
>70
Emotional Status
(SF-36IMCS)
<50
~50
Body Mass Index
Normal Weight «25)
Overweight (25-30)
Obese (30-34.9)
Morbidly Obese (>35)
Narcotics
Yes
No
Co-morbidities
P-values represent t-test results comparing baseline and follow-up scores;
I month change in pain ~ 1 month SF-36 Pain - baseline SF-36 Pain;
3 months change in pain ~ 3 months SF-36 Pain - baseline SF-36 Pain;
• One way ANOVA p-vaiues ~ .05; "One way ANOVA p-values ~ .10. Compared variabie categories (i.e. male v.
female)
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Table 4.3: Predictors of change in pain over 3 months (multiple regression)
SF-36 Pain
Patient characteristics change
J}-(950/0CI)r------------------
-c:-::--=-.,...,-------,------:----=--:--::'--:-...,.....,..~--
BMI (obese vs. non-obese) 7.9 (1.0,14.8) *
MCS baseline «50 vs. ~50) 14.1 (6.9,21.3) *
Age (60-69, vs. 70+) 0.25 (-6.7, 7.2)
Gender (male vs. female) -0.39 (-8.2, 7.4)
Based on linear mixed effects model analysis; *p<.05;
Figure 4.3: Mean Pain scores at baseline, 1 month and 3 months
by emotional health status.
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Figure 4.4: Mean Pain scores at baseline, 1 month and 3 months by body mass index.
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DISCUSSION
This study provides new information about injection effectiveness in the older adult
population. Despite the fact that lumbar spinal stenosis occurs more frequently in aging adults 14
and affects 5 of every 1,000 Americans over age 50 IS, the effectiveness of injection treatment is
understudied. This study provides much needed quantitative information on the effectiveness on
pain relief of injection therapy using steroids and analgesics.
There were three main findings of this study. First, significant pain relief was observed
in older adults for up to three months after injection treatment. Second, patients with high
emotional status experienced more pain relief than patients with low emotional status. Third,
pain relief varied by body mass index.
Body mass index has been associated with comorbidities, including osteoarthritis and
back pain, in previous literature 3S. Obesity has also been associated with higher fatigue and less
activity, especially in patients with knee osteoarthritis 36. In this study, patients who were obese
to morbidly obese experienced more pain relief than lighter patients. Variations in response to
pain treatment could be associated with lower activity levels in obese patients, resulting in less
pain. The effects of injections could also have been less effective in patients with a history of
hip or knee arthritis, as noted in an earlier study by Bischoff-Ferrari 37. There are two possible
explanations for this response: First, arthritis may be more advanced in these patients than in
patients who have not had hip or knee surgery, which may have affected their response to
injection medications. Second, referred hip and/or knee pain may confound pain relief due to
local treatment of the lumbar stenosis. Inconsistent results found in these groups could also be
due to the size of the sample, especially when distributed among sub-categories.
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High emotional status was found to be strongly associated with greater improvement in
pain at one month. This finding parallels findings in previous studies examining other
musculoskeletal disorders, including total knee replacement 38 and total hip replacement 37.
However, this is the first study on older patients diagnosed with lumbar spinal stenosis to
produce these results. It is important to note that patients with low emotional health had more
pain at baseline (PCS=21.3) compared to patients with high emotional health (31.4). Thus, it is
not clear if greater pain preceded the lower emotional health or vice versa. This will provide
clinicians with valuable information when screening their patients at baseline. If emotional
status has impact on how well patients respond to injection treatment, clinicians may discuss this
association with patients. This change may maximize the benefit of injection treatment in this
sub-population of aging patients.
A limitation of this study was that the effects of lumbar spinal stenosis severity could not
be determined. Stenosis severity has been documented in previous studies using Magnetic
Resonance Imaging (MRI) films for measurement 13,32,33. In this study, only a minority of
original MRI films were available to the study team for review and severity information could
not be consistently collected. However, MRI reports were available and reviewed to confirm
diagnosis. Reports that indicated disc related LSS as being the primary diagnosis were not
included in the study. Future research projects examining injection treatment for lumbar spinal
stenosis should determine image availability before data collection begins.
A second limitation was the study size. Enrollment of study participants was limited to
one location over a relatively short period of time (6 months). The inclusion of patients from
only one study center may affect the generalizability ofthe response to treatment found in this
cohort. However, this was the first study to examine the results of injection treatment in older
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adults with a diagnosis of LSS specifically caused by degenerative changes. In addition, the
study site was a clinic specifically designed to treat patients with back pain, serving a diverse
population in a large metropolitan city in the northeast. As the only spine center in the area, the
patient population is representative ofthe surrounding area. These results may be used in the
design of future, multicenter studies.
A third limitation of this study included a lack of sufficient power to determine the
differences in treatment effects within these sub-categories (BMI and emotional health), making
it impossible to make recommendations according to specific conditions of the potential patients.
Future research should increase sample size to adequately examine the relationship between
patient characteristics and injection effectiveness, especially in regard to emotional health status
as a potential predictor of outcome.
Study design may also be considered a limitation. Ideally, a comparison group would
have provided the best information in determining injection treatment effectiveness in this
cohort. However, a randomized control design poses problems with invasive procedures such as
injection treatment. Many clinicians recommend injection treatment for lower back pain as a last
resort before surgery. Randomizing patients to either surgery or injection treatment may likely
cause some ethical considerations in study design. Selection bias was also a potential limitation
of this study. Though consideration of this potential problem was addressed in study design (by
enrolling all patients who met study inclusion criteria and agreed to participate), patients who
chose to participate may have had different characteristics from those who refused. However,
patients who agreed to participate were compared to patients who did not agree, and had similar
characteristics (age, gender).
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Additional information about other patient characteristics such as socioeconomic status
and lifestyle may have also been useful in assessing differences in response to injection
treatment. However, in this study, patient surveys were completed within a short period oftime
before entering the injection room and time was limited. Future studies may benefit from
collecting this information at a less sensitive time.
In general, pain scores improved substantially one month after treatment. Three months
after treatment, an improvement was seen as well, but not as strong as at one month. Clearly,
pain medications administered by injection did not have a lasting effect, but were still providing
some pain relief even after three months. Though this amount of pain relief will be satisfactory
for some patients, others may prefer a longer effect and may prefer surgery to injection
treatment. However, this information will be useful for clinicians who consider offering
injections as an option for their aging patients.
The results of this study suggest that injection treatment may reduce lower back pain in
older patients with lumbar spinal stenosis for up to three months or more. Treatment effects may
vary by patient characteristics which should be considered when referring patients to injection
treatments. To further examine potential predictors of achieving maximum pain relief, future
research should increase sample size. An important finding ofthis study was that good baseline
emotional health demonstrated a strong association with pain level following injection treatment.
Future research should take this important relationship into account in study design.
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CHAPTERS
Conclusion
Following a thorough search through clinical literature, several gaps were found about
the effectiveness of injection treatment in older adults. Only seven studies were located that
specifically examined older adults with lumbar spinal stenosis primarily caused by arthritic
changes. The goal of this project was to address the strengths and limitations of those studies, by
designing and carrying out a new study based on that information.
After careful review, it was determined there were several inconsistencies in past study
designs.
The first problem concerned the measurement of the outcome following injection treatment. The
primary concern for this treatment was to decrease or eliminate pain associated with lumbar
spinal stenosis. However, the majority of studies identified in the literature review used a simple
Visual Analogue Scale (VAS) or Numeric Pain Scale to obtain this measurement (n=5). This
was an important consideration in the design of our studies. As the Short Form 36 (SF-36) is an
established survey tool that has been extensively validated in a number of populations, including
degenerative arthritis and back pain, the Pain subscale score was deemed to be a more than
sufficient tool for assessing pain. VAS measurements are a standard screening tool in many
clinic settings, and were used in the design of our retrospective study simply because they were
available. However, in the design of our prospective study, the SF-36 Pain subscale was used to
obtain a more accurate measurement of pain.
The second concern for injection treatment was to increase function. Though this is
generally a secondary consideration following pain relief, function was also assessed using a
variety of methods, including the Roland Morris Disability Questionnaire, the Oswestry
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Disability Index (ODI) and walking tests. Since the ODI was designed to measure function in
patients with spinal disorders and has been reported as the "gold standard" for evaluating
function in patients with lower back pain 29, this survey tool was used in our prospective study as
well. The ODI served as a measurement of spine-specific function, and was also chosen to better
serve orthopedic audiences. To provide a general health measurement of function, the Physical
Component Score (PCS) of the SF-36 was used. It has also been recognized in SF-36 survey
guidelines 39 that additional surveys may be administered along with the SF-36 and
recommended that the SF-36 be placed before the second survey. These guidelines were
followed in our procedures for the prospective study.
Follow-up periods were also found to be varied in the previously reviewed articles. For
this reason, our retrospective study was a useful tool in determining what follow-up periods
would be reasonable and useful in the design of our prospective study design. The retrospective
study examined the rate and timing of second injections received by patients following their
initial injection. It was found that patients returned for second injections after approximately 3.7
months and that 57% of patients returned for injections within six months. Because of the
retrospective study design, the reasons for returning (or not returning) for a second injection
were not known. However, the results did show that the majority of patients desired to have a
second injection between three and six months (presumably, because their pain had returned).
Therefore, it was a reasonable conclusion to collect information on pain and function at three
months as a long term measurement, and at one month as a short term measurement. Indeed, the
results of both the pain and function studies did show marked improvements at one month, and
declining effects at three months, as expected.
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The second problem concerned the methods used for diagnosis of lumbar spinal stenosis
(LSS). Some studies used Magnetic Resonance Imaging (MRI), some used symptoms alone and
some used both. These methods for determining diagnosis were also important in assessing
severity of LSS. In addition, both the retrospective and prospective studies included only
patients diagnosed with LSS caused by degenerative changes or osteoarthritis (not disc
displacement). The review of MRI reports were important tools for both diagnosis and severity.
First, diagnosis was confirmed by MRI reports and clinical notes by the attending physiatrist. In
previous studies, diagnosis has been determined by both imaging and symptoms. However,
since MRI has been used most consistently, it was deemed to be the most accurate measurement
available, especially when confirmed with clinical notes about symptoms. Second, severity was
determined by measurements performed on the available images by a research orthopedic
resident. Studies published after the prospective study had begun used these techniques and thus
were incorporated into the study design. However, it was discovered that approximately 75% of
images were not available for viewing, and this variable was subsequently dropped from the
analysis. This discovery was an important lesson in the process of the study, as
recommendations for future similar studies will include confirming the presence of MRI before
data collection begins.
The third problem concerned the inclusion of a wide variety of age ranges in previous
studies. Though older patients were included in previous studies, they were not stratified in the
analyses and it was not possible to draw any conclusions based on age alone. The focus of our
studies was to gain more information about injection treatment in older people. Thus, both the
retrospective and prospective studies were limited to only patients aged 60 and over.
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Recommendations for future research included a focus on older people, as well as
including specific information about pain, function, complications and co-morbidities. Both the
retrospective and prospective studies focused specifically on older adults. The retrospective
study was designed to gather information about the use of injections in this age group and to
learn more about their characteristics (i.e. gender, age, BMI). The prospective studies were
designed to build on that information by determining follow-up periods as well as patient
characteristics that may be important in treatment response. The prospective studies clearly
defined pain and function by using established surveys in musculoskeletal research. Co-
morbidities were also assessed using a well established tool, the Charlson Comorbidity Index 30.
Though this index was designed to collect information about a wide variety of diseases and
conditions, a more refined profile about study patients may have been more useful. However, it
was not within the scope of this project to use a more specific tool. Future research may include
the use of a more detailed instrument. Complications were not collected in either the
retrospective or prospective studies. Information about complications in previous literature is
limited, but those that have been reported were minimal. Therefore, follow-up information was
limited to the surveys used for pain and function assessment only.
Another recommendation involved the potential use of randomized control designs to
further investigate the effectiveness of injection treatment. One study included in the literature
review used this study design 12. However, this study was not completed in the United States
and may not have been subjected to the same guidelines of our Institutional Review Board.
There would likely be ethical considerations with an invasive treatment such as spine injections,
and this design may be problematic in our institution and others.
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The results of both the retrospective and prospective studies showed several important
conclusions. First, the majority of patients over age 60 returned for a second injection within six
months ofthe first injection, and most returned just before four months. Second, patients over
age 70 did not return as soon as younger patients (aged 60 to 69). Third, patients experienced a
significant reduction in pain after one month, but pain relief was not as effective after three
months. Fourth, patients experienced a significant increase in function after one month, but there
was some decrease in function by three months. Fifth, good emotional health was associated
with more pain relief and better function over three months following treatment. These findings
will be important in the design and implementation of future studies examining injection
treatment in older adults. Based on these results, recommendations for future research include; a
larger, multicenter study; verification of MRI reports and images; a more extensive co-morbidity
index designed to cover a wider range of diseases and conditions; and, emotional health
screening and measurement (possibly including a more in depth tool in place of the SF-36 MCS).
With a more detailed and focused design, physicians and older adult patients will have more
information to make decisions about treatment for their lower back pain.
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